2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Hristos Kaimakliotis, MD, assistant professor, Indiana University School of Medicine, discusses predictive markers in bladder cancer.
Homologous recombination repair-deficiency (HRD) and cell cycle progression (CCP) have been identified in DNA repair pathways as potential predictors of tumor behaviors, says Kaimakliotis.
After investigating HRD and CCP assays, it was determined that higher CCP and HRD scores were associated with pathological complete responses (pCR) and decreased risk of recurrence.
In a mutation analysis, it was determined that P53 and RB1 mutations were associate with pCRs as well.
Related Content: